Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...